Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

Chronic Kidney Disease Clinical Trial

— HM-SIM4  

Official title:

Efficacy and Safety of Morning Intake of Simvast Controlled Release (CR) Tablet Versus Evening Intake of Zocor Tablet in Chronic Kidney Disease Stage(CKD)3, 4 and 5 Patients With Hyperlipidemia: A Randomized, Double-blind, Multicenter Phase 4 Trial (HM-SIM4)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01564875
• Other study ID #: HM-SIM4
• Status: Active, not recruiting
• Phase: Phase 4
• First received: March 23, 2012
• Last updated: March 26, 2012
• Start date: December 2010
• Est. completion date: May 2012

Study information

• Verified date: March 2012
• Source: Hanmi Pharmaceutical Company Limited
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Study design

• Multicenter, double-dummy, double-blinded, randomized, Phase 4 study

• Patients will be randomized to either a study group or a control group in a 1:1 ratio, and will be orally administered the assigned drugs

Study Objective

-The study is designed to demonstrate that efficacy and safety of morning dosing of Simvast Controlled Release (CR) Tab is not inferior to evening dosing of Zocor Tab in patients with stage 3,4,5 chronic kidney disease with hyperlipidemia

Primary objective

-to assess the percent change of LDL-C at Week 8 from baseline in Chronic Kidney Disease(CKD) stage 3,4,5 with hyperlipidemia subjects.

Description:

The secondary objectives of the study are as follows:

• to assess the change and percent change of TC, HDL-C, TG from baseline.

• to assess the accomplishment rate of therapeutic goals based on the therapeutic guidance for hyperlipidemia of the Korean Society of Lipidology and Atherosclerosis.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 122
• Est. completion date: May 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 75 Years

Eligibility

Inclusion criteria:

• Patient with age of 20 to 75 (inclusive)

• Patients with fasting serum lipid panels meeting the followings:

• At Visit 1 screening 100mg/dL = LDL-C < 220 mg/dL Triglyceride < 400mg/dL However, if the patient has been treated with antihyperlipidemics for 4 consecutive weeks or longer at the time of screening, it should be 100mg/ dL = LDL-C < 160 mg/dL.

• At Visit 2 screening 100mg/dL = LDL-C < 220 mg/dL Triglyceride < 400mg/dL

• Patients with CKD stage 3 to 5.

• Subjects considered requiring medication by the principal investigator based on the therapeutic -guidance for hyperlipidemia of the Korean Society of Lipidology and Atherosclerosis.

• Patients who understand the study procedures and signed the informed consent form.

Exclusion criteria:

• Patients with a hypersensitivity to HMG-CoA reductase inhibitor or any of its ingredients.

• Patients who consume more than 14 units of alcohol a week, who are considered to have a history of drug overdose within 12 months of screening by the investigator, or who abuse other drugs.

• Patients with the following history:

• Active gallbladder disease within 12 months of screening (patients who had cholecystectomy are eligible for the study).

• Pancreatitis or liver disease (AST or ALT > 2 times the upper limit of the normal range at Visits 1 and 2).

• Patients with uncontrolled diabetes mellitus (HbA1c = 9.0 %).

• Patients with hypotension (systolic blood pressure< 90mmHg or diastolic blood pressure<50mmHg).

• Patients with uncontrolled hypertension: mean systolic blood pressure (SBP)> 160mmHg or mean diastolic blood pressure (DBP) > 100mmHg at Visit 2.

• Patients with myocardial infarction or who had coronary artery bypass or angioplasty within 6 months before screening.

• Patients who had stroke, transient ischemic attack (TIA), or deep vein thrombosis (DVT) within 6 months of screening.

• Patients who had been treated for carotid artery disease, peripheral artery disease, or abdominal aortic aneurysm.

• Patients with serious heart disease (patients with NYHA class (Attachment 4) III or IV congestive heart failure, unstable angina pectoris, or acute myocardial infarction).

• Patients who were diagnosed with malignancy within 5 years or who have active tumors.

• Patients with fibromyalgia, myopathy, rhadomyolysis, or sudden muscle pain, or patients who experienced adverse events during the previous treatment with statins.

• Patients with mental illnesses considered by the investigator serious enough to adversely affect the patients' participation in the study.

• Patients with uncontrolled primary hypothyroidism.

• Patients with active peptic ulcer disease.

• Patients with gastrointestinal conditions that may restrict drug absorptions, such as chronic diarrhea, inflammatory colic disease, partial ileal bypass, gastrorrhaphy, or gastric banding.

• Screening CPK level > 3 times the upper limit of the normal range.

• Patients on immunosuppressives after kidney transplantation.

• Patients who need to be on immunosuppressives for other reasons.

• Patients who have participated in another clinical trial within the last 4 weeks of screening (except those who participated in clinical trials including observational studies that do not involve interventions such as medication).

• Pregnant women, lactating women, or women of childbearing potential who do not use appropriate contraceptives.

• Patients currently on dialysis.

• Other patients considered ineligible by the principal investigator and investigators.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Kidney Disease
• Hyperlipidemia
• Hyperlipidemias
• Kidney Diseases
• Renal Insufficiency, Chronic

Intervention

Drug:
• Simvast CR
Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
• Zocor
Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.

Locations

Country	Name	City	State
Korea, Republic of	Hallym University Medical Center	Anyang-si	Gyeonggi-do
Korea, Republic of	Inje University Ilsan Paik Hospital	Goyang-si	Gyeonggi-do
Korea, Republic of	Gachon University Gil Hospital	Incheon
Korea, Republic of	Eulji General Hospital	Seoul
Korea, Republic of	Hanyang University Seoul Hospital	Seoul
Korea, Republic of	Korea University Anam Hospital	Seoul
Korea, Republic of	Seoul National University Hospital	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Hanmi Pharmaceutical Company Limited

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change of LDL-C	Percent change of LDL-C at Week 8 from baseline	8 weeks	Yes
Secondary	Change and percent change of TC, HDL-C, TG	Change and percent change of TC, HDL-C, TG from baseline.	8 weeks	Yes
Secondary	Accomplishment rate of therapeutic goals	-Accomplishment rate of therapeutic goals based on the therapeutic guidance for hyperlipidemia of the Korean Society of Lipidology and Atherosclerosis.	8 weeks	Yes